NICE expands breast cancer drug options
The National Institute for Health and Clinical Excellence has announced that it is recommending the use of the hormonal therapies anastrozole, exemestane and letrozole for the treatment of women with early oestrogen receptor-positive invasive breast cancer following surgery to remove the tumours.The drugs will be available alongside existing breast cancer ...
You need to be a subscriber to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All HSJ news by sector, topic & region
- Breaking News announcements
- App for mobile and offline reading
- Comment and Daily Insights newsletters
- Regional roundup newsletters
- Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
- 10 expert briefings every fortnight (Premium only)
Already a subscriber? Sign into your account here